Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVGN-116
- Development stage
- Preclinical
- Lead developer
- Tevogen Bio
- Modality
- Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TVGN-116 is an investigational, ExacTcell-derived cytotoxic T lymphocyte (CTL) therapy being developed by Tevogen Bio Holdings. It is designed to target Hepatitis B Virus (HBV) antigens to prevent the development of liver cancer (hepatocellular carcinoma) in patients with high-risk chronic Hepatitis B. The therapy utilizes Tevogen's proprietary ExacTcell platform to generate off-the-shelf, non-genetically modified, multi-antigen targeting T cells. By specifically identifying and eliminating HBV-infected cells, TVGN-116 aims to reduce the viral reservoir and the chronic inflammation that leads to oncogenesis. The program is currently in the preclinical stage of development.
- Other names
- ExacTcell EBV-specific cytotoxic CD8+ T lymphocyte therapy
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on TVGN-116.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVGN-116.